Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies

Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies

Bispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer promising therapeutic options for various diseases by targeting multiple pathways. The favorable pharmacokinetic (PK) properties of monoclonal antibodies (mAbs) are crucial, as they directly influence patien...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kristina M.J. Aertker, Minu Ravindra Pilvankar, Tobias M. Prass, Michaela Blech, Fabian Higel, Srinath Kasturirangan
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Biophysical assessment bispecific antibody FcRn in silico developability pharmacokinetics (PK)
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2318817
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
by: Johannes Reusch, et al.
Published: (2024-12-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody
by: Eva Schlein, et al.
Published: (2024-12-01)

Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report
by: Huasheng Huang, et al.
Published: (2025-01-01)

scFv Antibody: Principles and Clinical Application
by: Zuhaida Asra Ahmad, et al.
Published: (2012-01-01)

Discovery and in vitro characterization of a human anti-CD36 scFv
by: Cecilia Mata-Cruz, et al.
Published: (2025-02-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01)

Telomerase and cells youth.
by: Alexander Benavides Couto, et al.
Published: (2008-08-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms
by: Marianne Bachmann Salvy, et al.
Published: (2024-12-01)

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01)

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
by: Michael Mullin, et al.
Published: (2024-12-01)

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
by: Peter Jung, et al.
Published: (2024-12-01)

In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks
by: Hui-Lin Zhang, et al.
Published: (2025-01-01)

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion
by: Chongwei Xie, et al.
Published: (2025-03-01)

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Key Lime Growing in the Florida Home Landscape
by: Jonathan H. Crane
Published: (2011-01-01)

Key Lime Growing in the Florida Home Landscape
by: Jonathan H. Crane
Published: (2011-01-01)

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β
by: Rebecca Faresjö, et al.
Published: (2024-12-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration
by: Andrés de la Rosa, et al.
Published: (2025-01-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies
by: Han-ul Kim, et al.
Published: (2025-01-01)

With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process
by: Silvia Crescioli, et al.
Published: (2025-12-01)

Intermediate Physics for Medicine and Biology /
by: Hobbie, Russel K
Published: (1997)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration
by: Paul Tamburini, et al.
Published: (2024-12-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB
by: P. S. Rao, et al.
Published: (2024-02-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)